Quanterix Corporation (QTRX)

NASDAQ: QTRX · Real-Time Price · USD
3.390
0.00 (0.00%)
At close: Apr 14, 2026, 4:00 PM EDT
3.390
0.00 (0.00%)
After-hours: Apr 14, 2026, 4:11 PM EDT
Market Cap159.13M -39.4%
Revenue (ttm)138.90M +1.1%
Net Income-107.15M
EPS-2.51
Shares Out 46.94M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,380,108
Open3.450
Previous Close3.390
Day's Range3.340 - 3.575
52-Week Range3.235 - 8.770
Beta1.32
AnalystsHold
Price Target8.00 (+135.99%)
Earnings DateMay 11, 2026

About QTRX

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, s... [Read more]

Sector Healthcare
IPO Date Dec 7, 2017
Employees 450
Stock Exchange NASDAQ
Ticker Symbol QTRX
Full Company Profile

Financial Performance

In 2025, Quanterix's revenue was $138.90 million, an increase of 1.07% compared to the previous year's $137.42 million. Losses were -$107.15 million, 178.1% more than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for QTRX stock is "Hold." The 12-month stock price target is $8.0, which is an increase of 135.99% from the latest price.

Price Target
$8.0
(135.99% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Quanterix Corporation Announces Date of 2026 Annual Meeting

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Co...

18 days ago - Business Wire

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...

6 weeks ago - Business Wire

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on...

6 weeks ago - Business Wire

Quanterix to Participate in Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...

6 weeks ago - Business Wire

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i...

7 weeks ago - Business Wire

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has...

2 months ago - Business Wire

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...

2 months ago - Business Wire

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...

3 months ago - Business Wire

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...

3 months ago - Business Wire

Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced public...

4 months ago - Business Wire

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diag...

5 months ago - Business Wire

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the pu...

5 months ago - Business Wire

Quanterix Releases Financial Results for the Third Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ...

5 months ago - Business Wire

Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...

5 months ago - Business Wire

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Departmen...

8 months ago - Business Wire

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadershi...

8 months ago - Business Wire

Quanterix Releases Financial Results for the Second Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the s...

8 months ago - Business Wire

Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen...

9 months ago - Business Wire

Quanterix Announces Cooperation Agreement with Kent Lake Capital

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announc...

9 months ago - Business Wire

Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commerc...

9 months ago - Business Wire

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announ...

10 months ago - Business Wire

Quanterix Expands Reach with IVD and Large Reference Labs

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoas...

10 months ago - Business Wire

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company...

10 months ago - PRNewsWire

Quanterix to Present at Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe...

11 months ago - Business Wire

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company"...

Other symbols: AKYA
11 months ago - PRNewsWire